HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245

Benzinga Newsdesk www.benzinga.com Neutral 49.7%

Neg 0% Neu 49.7% Pos 0%

HC Wainwright & Co. analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $245.